Cannabis
SpeakEasy Closes Second Tranche of Private Placement
SpeakEasy Cannabis Club Ltd. (CSE: EASY) (Frankfurt: 39H) (the “Company” or “SpeakEasy“) is pleased to announce that it has closed the second tranche of its previously announced non-brokered private placement (the “Private Placement“) for deemed aggregate gross proceeds of $1,392,535.70. The second tranche closing consisted of the issuance of 3,763,610 units of the Company (the “Units“) at a price of $0.37 per Unit.
Each Unit consists of one common share in the capital of the Company (a “Common Share“) and one Common Share purchase warrant (each whole warrant, a “Warrant“). Each Warrant will entitle the holder thereof to acquire an additional Common Share at a price of $0.60 for a period of 24 months from closing.
In connection with the completion of the second tranche of the Private Placement, the Company paid cash finders fees of $47,952 and issued 129,600 non-transferable broker warrants (the “Broker Warrants“). Each Broker Warrant entitles the holder to acquire one Common Share at an exercise price of $0.60 per share for a period of 24 months following closing.
As part of the Private Placement, the Company also issued an additional 877,973 Common Shares in settlement of a bona fide debts to an arm’s length creditors in the aggregate amount of $324,850.
The securities issued by the Company under the second tranche of the Private Placement are subject to restrictions on resale in accordance with applicable securities laws. These restrictions will expire on February 16, 2021. The Private Placement is subject to final acceptance by the Canadian Securities Exchange.
The Company also announces that it has granted incentive stock options (the “Options“) to a consultant of the Company to acquire an aggregate of up to 417,162 Common Shares for a period of 24 months following at an exercise price of $0.60/share. In addition, the Company has granted Options to an officer and certain employees of the company to acquire an aggregate of up to 1,000,000 Common Shares for a period of five years at an exercise price of $0.48/share.
-
Cannabis1 week ago
Mikra Announces Partnership with Virun NutraBiosciences Inc. and Releases CELLF 2.0
-
Cannabis1 week ago
IM Cannabis Reports First Quarter Financial Results
-
Innocan1 week ago
Innocan Pharma Reports Breakthrough in a Pre-Clinical Trial: Liposomal-CBD Injection Restores Mobility to an Amputee Female Donkey
-
Cannabis5 days ago
Avicanna Announces Results of Study in Patients with Epidermolysis Bullosa
-
Cannabis5 days ago
Global Legal Marijuana Strategic Business Report 2024: A $125+ Billion Market by 2030 Featuring Aphria, Aurora Cannabis, Beacon Medical, Canopy Growth, Cronos, OrganiGram, Tikun Olam, Tilray, Wayland
-
Cannabis4 days ago
North America Legal Cannabis Industry Report 2024: Market to Grow at a CAGR of 26.65% During 2023-2032, Bank Loans Boosting Business Growth
-
Cannabis3 days ago
Polyethylene Films Packaging Market Size to Worth USD 139.98 Bn by 2032
-
Cannabis2 days ago
Rubicon Organics Reports Q1 2024 Financial Results